The present invention relates to reagents and methods for the diagnosis, prognosis and treatment of
cancer. Specifically, the present invention relates to the use of proteins encoding transmembrane superfamily member 6 (TM4SF6), synaptophysin-like
protein (SYPL), stomatin-like 2 (STOML2), Ras-associated GTP-
binding protein (RAGA),
nucleotide-sensitive
Chloride channel 1A (CLNS1A), prion
protein (p27-30) (PRNP),
guanine nucleotide-
binding protein β2-like 1 (GNB2L1),
guanine nucleotide-
binding protein 4 (GNG4), integral membrane
protein 2B (ITM2B),
integral membrane protein 1 (ITM1), transmembrane 9 superfamily member 2 (TM9SF2),
opiate receptor-like 1 protein (OPRL1), low-density
lipoprotein receptor-related protein 4 (LRP4),
human kidney Nucleic acid and
amino acid sequences of glomerular epithelin 1 (GLEPP1),
toll-like
receptor 3 (TLR3), and / or
zona pellucida glycoprotein 3A (ZP3) for early and advanced non-
steroid-specific
cancer diagnosis,
cancer prognosis, and For screening therapeutic agents that modulate the
gene expression and / or
biological activity of the protein. The invention further relates to biotechniques designed to inhibit
gene expression and / or
biological activity of said proteins, including the use of agents identified in the screening assays described herein, vector delivery of antisense
polynucleotide sequences, and the
Antibody targeting the protein. In specific embodiments, the protein is of human origin.